Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/35917
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorANTUNES, Fernanda
dc.contributor.authorPEREIRA, Gustavo J. S.
dc.contributor.authorSAITO, Renata F.
dc.contributor.authorV, Marcus Buri
dc.contributor.authorGAGLIARDI, Mara
dc.contributor.authorBINCOLETTO, Claudia
dc.contributor.authorCHAMMAS, Roger
dc.contributor.authorFIMIA, Gian Maria
dc.contributor.authorPIACENTINI, Mauro
dc.contributor.authorCORAZZARI, Marco
dc.contributor.authorSMAILI, Soraya Soubhi
dc.date.accessioned2020-06-01T14:50:48Z-
dc.date.available2020-06-01T14:50:48Z-
dc.date.issued2020
dc.identifier.citationCELLS, v.9, n.3, article ID 640, 18p, 2020
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/35917-
dc.description.abstractSkin melanoma is one of the most aggressive and difficult-to-treat human malignancies, characterized by poor survival rates, thus requiring urgent novel therapeutic approaches. Although metabolic reprogramming has represented so far, a cancer hallmark, accumulating data indicate a high plasticity of cancer cells in modulating cellular metabolism to adapt to a heterogeneous and continuously changing microenvironment, suggesting a novel therapeutic approach for dietary manipulation in cancer therapy. To this aim, we exposed melanoma cells to combined nutrient-restriction/sorafenib. Results indicate that cell death was efficiently induced, with apoptosis representing the prominent feature. In contrast, autophagy was blocked in the final stage by this treatment, similarly to chloroquine, which also enhanced melanoma cell sensitization to combined treatment. Energy stress was evidenced by associated treatment with mitochondrial dysfunction and glycolysis impairment, suggesting metabolic stress determining melanoma cell death. A reduction of tumor growth after cycles of intermittent fasting together with sorafenib treatment was also observed in vivo, reinforcing that the nutrient shortage can potentiate anti-melanoma therapy. Our findings showed that the restriction of nutrients by intermittent fasting potentiates the effects of sorafenib due to the modulation of cellular metabolism, suggesting that it is possible to harness the energy of cancer cells for the treatment of melanoma.eng
dc.description.sponsorshipItalian Association for Cancer Research-AIRCAssociazione Italiana per la Ricerca sul Cancro (AIRC) [MFAG 11749, 17404, 15244]
dc.description.sponsorshipItalian Ministry of University and Research (FIRB Accordi di Programma 2011)Ministry of Education, Universities and Research (MIUR) [PRIN 2015 20152CB22L]
dc.description.sponsorshipItalian Ministry of HealthMinistry of Health, Italy
dc.description.sponsorshipRussian Government Program for the Recruitment of the leading scientists into the Russian Institutions of Higher Education [14. W03.31.0029]
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [FAPESP-2012/08273-3, 2013/20073-2, 2017/10863-7]
dc.description.sponsorshipConselho Nacional de Desenvolvimento Cientifico e TecnologicoNational Council for Scientific and Technological Development (CNPq) [CNPq-163612/2013-7, PVE 401236/2014-5, PVE 401141/2014-4]
dc.description.sponsorshipCoordenacao de Aperfeicoamento de Pessoal deNivel Superior-Brasil (CAPES)CAPES
dc.description.sponsorshipFinanciadora de Estudos e Projetos (FINEP)Ciencia Tecnologia e Inovacao (FINEP)
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
dc.language.isoeng
dc.publisherMDPIeng
dc.relation.ispartofCells
dc.rightsopenAccesseng
dc.subjectapoptosiseng
dc.subjectenergy stresseng
dc.subjectmelanomaeng
dc.subjectautophagyeng
dc.subjectsorafenibeng
dc.subject.otherdown-regulationeng
dc.subject.othercancer-cellseng
dc.subject.othermolecular-mechanismseng
dc.subject.othertumor-growtheng
dc.subject.otherer stresseng
dc.subject.otherautophagyeng
dc.subject.otherinhibitioneng
dc.subject.otherapoptosiseng
dc.subject.othermetabolismeng
dc.subject.otherambra1eng
dc.titleEffective Synergy of Sorafenib and Nutrient Shortage in Inducing Melanoma Cell Death through Energy Stresseng
dc.typearticleeng
dc.rights.holderCopyright MDPIeng
dc.identifier.doi10.3390/cells9030640
dc.identifier.pmid32155825
dc.subject.wosCell Biologyeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
hcfmusp.author.externalANTUNES, Fernanda:Univ Fed Sao Paulo, Paulista Sch Med, Dept Pharmacol, BR-04021001 Sao Paulo, Brazil
hcfmusp.author.externalPEREIRA, Gustavo J. S.:Univ Fed Sao Paulo, Paulista Sch Med, Dept Pharmacol, BR-04021001 Sao Paulo, Brazil
hcfmusp.author.externalV, Marcus Buri:Univ Fed Sao Paulo, Paulista Sch Med, Dept Mol Biol, BR-04021001 Sao Paulo, Brazil
hcfmusp.author.externalGAGLIARDI, Mara:Univ Piemonte Orientale, Dept Hlth Sci DISS, I-28100 Novara, Italy; Ctr Translat Res Autoimmune & Allerg Dis CAAD, I-28100 Novara, Italy
hcfmusp.author.externalBINCOLETTO, Claudia:Univ Fed Sao Paulo, Paulista Sch Med, Dept Pharmacol, BR-04021001 Sao Paulo, Brazil
hcfmusp.author.externalFIMIA, Gian Maria:Natl Inst Infect Dis IRCCS Lazzaro Spallanzani, Dept Epidemiol & Preclin Res, I-00149 Rome, Italy; Univ Roma La Sapienza, Dept Mol Med, I-00185 Rome, Italy
hcfmusp.author.externalPIACENTINI, Mauro:Natl Inst Infect Dis IRCCS Lazzaro Spallanzani, Dept Epidemiol & Preclin Res, I-00149 Rome, Italy; Russian Acad Sci, Inst Cytol, St Petersburg 199034, Russia
hcfmusp.author.externalCORAZZARI, Marco:Univ Piemonte Orientale, Dept Hlth Sci DISS, I-28100 Novara, Italy; Ctr Translat Res Autoimmune & Allerg Dis CAAD, I-28100 Novara, Italy; Univ Piemonte Orientale, Dept Hlth Sci, I-28100 Novara, Italy; Univ Piemonte Orientale, IRCAD, I-28100 Novara, Italy
hcfmusp.author.externalSMAILI, Soraya Soubhi:Univ Fed Sao Paulo, Paulista Sch Med, Dept Pharmacol, BR-04021001 Sao Paulo, Brazil
hcfmusp.description.articlenumber640
hcfmusp.description.issue3
hcfmusp.description.volume9
hcfmusp.origemWOS
hcfmusp.origem.idWOS:000529337400117
hcfmusp.origem.id2-s2.0-85083844827
hcfmusp.publisher.cityBASELeng
hcfmusp.publisher.countrySWITZERLANDeng
hcfmusp.relation.referenceAbildgaard C, 2015, TRENDS MOL MED, V21, P164, DOI 10.1016/j.molmed.2014.12.007eng
hcfmusp.relation.referenceAntonioli M, 2017, TRENDS BIOCHEM SCI, V42, P28, DOI 10.1016/j.tibs.2016.09.008eng
hcfmusp.relation.referenceAntonioli M, 2014, DEV CELL, V31, P734, DOI 10.1016/j.devcel.2014.11.013eng
hcfmusp.relation.referenceAntunes F, 2018, CHEM-BIOL INTERACT, V281, P89, DOI 10.1016/j.cbi.2017.12.027eng
hcfmusp.relation.referenceAntunes F, 2017, BIOCHEM BIOPH RES CO, V485, P16, DOI 10.1016/j.bbrc.2016.09.149eng
hcfmusp.relation.referenceArmstrong JL, 2011, CLIN CANCER RES, V17, P2216, DOI 10.1158/1078-0432.CCR-10-3003eng
hcfmusp.relation.referenceAustin M, 2005, J BIOL CHEM, V280, P33280, DOI 10.1074/jbc.M508187200eng
hcfmusp.relation.referenceBhattacharya B, 2016, BRIT J PHARMACOL, V173, P970, DOI 10.1111/bph.13422eng
hcfmusp.relation.referenceBianchi G, 2015, ONCOTARGET, V6, P11806, DOI 10.18632/oncotarget.3688eng
hcfmusp.relation.referenceBonuccelli G, 2010, CELL CYCLE, V9, P3506, DOI 10.4161/cc.9.17.12731eng
hcfmusp.relation.referenceBull VH, 2012, J PROTEOME RES, V11, P1609, DOI 10.1021/pr200790eeng
hcfmusp.relation.referenceChae YK, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0349-3eng
hcfmusp.relation.referenceChaube B, 2015, CELL DEATH DISCOV, V1, DOI 10.1038/cddiscovery.2015.63eng
hcfmusp.relation.referenceChen YS, 2015, MOL MED REP, V12, P1645, DOI 10.3892/mmr.2015.3623eng
hcfmusp.relation.referenceCorazzari M, 2015, CELL DEATH DIFFER, V22, P946, DOI 10.1038/cdd.2014.183eng
hcfmusp.relation.referenceCorazzari M, 2013, SEMIN CANCER BIOL, V23, P337, DOI 10.1016/j.semcancer.2013.07.001eng
hcfmusp.relation.referenceCorazzari M, 2012, AUTOPHAGY, V8, P1255, DOI 10.4161/auto.20671eng
hcfmusp.relation.referenceDamy SB, 2010, REV ASSOC MED BRAS, V56, P103, DOI 10.1590/S0104-42302010000100024eng
hcfmusp.relation.referenceDang CV, 2012, GENE DEV, V26, P877, DOI 10.1101/gad.189365.112eng
hcfmusp.relation.referenceDi Biase S, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2015.1117701eng
hcfmusp.relation.referenceDirks WG, 2010, INT J CANCER, V126, P303, DOI 10.1002/ijc.24999eng
hcfmusp.relation.referenceDwarakanath BS, 2009, J CANCER RES THER, V5, P21, DOI 10.4103/0973-1482.55136eng
hcfmusp.relation.referenceEckelman WC, 2007, NUCL MED BIOL, V34, P229, DOI 10.1016/j.nucmedbio.2007.01.005eng
hcfmusp.relation.referenceElgendy M, 2015, AUTOPHAGY, V11, P581, DOI 10.1080/15548627.2015.1029836eng
hcfmusp.relation.referenceEscudier B, 2014, ANN ONCOL, V25, P49, DOI 10.1093/annonc/mdu259eng
hcfmusp.relation.referenceFan LX, 2013, BBA-GEN SUBJECTS, V1830, P5175, DOI 10.1016/j.bbagen.2013.07.010eng
hcfmusp.relation.referenceFarooque A, 2009, J CANCER RES THER, V5, P32, DOI 10.4103/0973-1482.55138eng
hcfmusp.relation.referenceFecteau JF, 2012, MOL MED, V18, P19, DOI 10.2119/molmed.2011.00164eng
hcfmusp.relation.referenceFumarola C, 2013, BREAST CANCER RES TR, V141, P67, DOI 10.1007/s10549-013-2668-xeng
hcfmusp.relation.referenceGagliardi M, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2143-7eng
hcfmusp.relation.referenceGiglio P, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1466765eng
hcfmusp.relation.referenceGiglio P, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.995016eng
hcfmusp.relation.referenceGojo I, 2002, CLIN CANCER RES, V8, P3527eng
hcfmusp.relation.referenceGuadarrama-Orozco JA, 2016, CLIN TRANSL ONCOL, V18, P863, DOI 10.1007/s12094-015-1469-6eng
hcfmusp.relation.referenceHao CY, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007325eng
hcfmusp.relation.referenceKatz SI, 2009, CANCER BIOL THER, V8, P2406, DOI 10.4161/cbt.8.24.10824eng
hcfmusp.relation.referenceKharaziha P, 2015, ONCOTARGET, V6, P37066, DOI 10.18632/oncotarget.5797eng
hcfmusp.relation.referenceKoppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038eng
hcfmusp.relation.referenceLachaier E, 2014, ANTICANCER RES, V34, P6417eng
hcfmusp.relation.referenceLalaoui N, 2015, SEMIN CELL DEV BIOL, V39, P63, DOI 10.1016/j.semcdb.2015.02.003eng
hcfmusp.relation.referenceLee C, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003293eng
hcfmusp.relation.referenceLevesque S, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1591878eng
hcfmusp.relation.referenceLiu XY, 2016, CELL MOL NEUROBIOL, V36, P1197, DOI 10.1007/s10571-015-0318-zeng
hcfmusp.relation.referenceLongo VD, 2014, CELL METAB, V19, P181, DOI 10.1016/j.cmet.2013.12.008eng
hcfmusp.relation.referenceLouandre C, 2015, CANCER LETT, V356, P971, DOI 10.1016/j.canlet.2014.11.014eng
hcfmusp.relation.referenceMarino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735eng
hcfmusp.relation.referenceOliverio S, 2014, AMINO ACIDS, V46, P2767, DOI 10.1007/s00726-014-1821-0eng
hcfmusp.relation.referencePagliarini V, 2012, CELL DEATH DIFFER, V19, P1495, DOI 10.1038/cdd.2012.27eng
hcfmusp.relation.referencePagliarini V, 2015, J CELL SCI, V128, P1166, DOI 10.1242/jcs.164103eng
hcfmusp.relation.referencePanka DJ, 2006, CANCER RES, V66, P1611, DOI 10.1158/0008-5472.CAN-05-0808eng
hcfmusp.relation.referencePeng YF, 2013, AUTOPHAGY, V9, P2056, DOI 10.4161/auto.26398eng
hcfmusp.relation.referenceRamirez-Labrada A, 2015, CLIN TRANSL ONCOL, V17, P121, DOI 10.1007/s12094-014-1201-yeng
hcfmusp.relation.referenceRaoul JL, 2018, CANCER TREAT REV, V68, P16, DOI 10.1016/j.ctrv.2018.05.006eng
hcfmusp.relation.referenceRatnikov BI, 2017, ONCOGENE, V36, P147, DOI 10.1038/onc.2016.198eng
hcfmusp.relation.referenceRoss FA, 2017, CELL CHEM BIOL, V24, P813, DOI 10.1016/j.chembiol.2017.05.021eng
hcfmusp.relation.referenceSafdie F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044603eng
hcfmusp.relation.referenceShimizu S, 2012, INT J CANCER, V131, P548, DOI 10.1002/ijc.26374eng
hcfmusp.relation.referenceSimone BA, 2013, FUTURE ONCOL, V9, P959, DOI [10.2217/fon.13.31, 10.2217/FON.13.31]eng
hcfmusp.relation.referenceSottnik JL, 2011, CLIN EXP METASTAS, V28, P865, DOI 10.1007/s10585-011-9417-5eng
hcfmusp.relation.referenceSuliman HB, 2015, PHARMACOL REV, V68, P20, DOI 10.1124/pr.115.011502eng
hcfmusp.relation.referenceTan ZQ, 2016, MOL CANCER THER, V15, P774, DOI 10.1158/1535-7163.MCT-15-0621eng
hcfmusp.relation.referenceWard PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014eng
hcfmusp.relation.referenceWeinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107eng
hcfmusp.relation.referenceWeng CJ, 2005, J BIOL CHEM, V280, P10491, DOI 10.1074/jbc.M412819200eng
hcfmusp.relation.referenceXu XD, 2015, ONCOL RES TREAT, V38, P117, DOI 10.1159/000375435eng
hcfmusp.relation.referenceYoule RJ, 2012, SCIENCE, V337, P1062, DOI 10.1126/science.1219855eng
hcfmusp.relation.referenceZhang CG, 2017, J BIOL CHEM, V292, P15105, DOI 10.1074/jbc.M117.783175eng
dc.description.indexMEDLINEeng
dc.identifier.eissn2073-4409
hcfmusp.citation.scopus7-
hcfmusp.scopus.lastupdate2024-03-29-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MDR
Departamento de Radiologia - FM/MDR

Artigos e Materiais de Revistas Científicas - HC/ICESP
Instituto do Câncer do Estado de São Paulo - HC/ICESP

Artigos e Materiais de Revistas Científicas - LIM/24
LIM/24 - Laboratório de Oncologia Experimental

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar


Files in This Item:
File Description SizeFormat 
art_ANTUNES_Effective_Synergy_of_Sorafenib_and_Nutrient_Shortage_in_2020.PDFpublishedVersion (English)2.84 MBAdobe PDFThumbnail
View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.